Research progress and challenges of the PD-1/PD-L1 axis in gliomas

Area of Science:

• Oncology
• Immunology
• Neuro-oncology

Background:

• Programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors represent novel therapeutic strategies for advanced cancers.
• While showing progress in some glioma clinical trials, PD-1/PD-L1 inhibitors have not yet demonstrated convincing clinical efficacy in gliomas.

Purpose of the Study:

• To review the current research on the PD-1/PD-L1 pathway in gliomas.
• To elucidate the complex expression and regulation of PD-1/PD-L1 within the glioma microenvironment.
• To examine immune infiltration in the immunosuppressive glioma microenvironment and the application of PD-1/PD-L1 inhibitors in clinical trials.

Main Methods:

• Literature review of PD-1/PD-L1 pathway research in gliomas.
• Analysis of expression levels and regulatory mechanisms of PD-1/PD-L1 in the glioma microenvironment.
• Assessment of immune cell infiltration and the impact of PD-1/PD-L1 inhibitors in clinical trials.

Main Results:

• PD-1/PD-L1 expression is complex within the glioma microenvironment.
• The glioma microenvironment is characterized by significant immunosuppression.
• Clinical efficacy of PD-1/PD-L1 inhibitors in gliomas is currently limited.

Conclusions:

• Understanding PD-1/PD-L1 dynamics in gliomas is crucial for improving immunotherapy.
• Further research is needed to overcome the immunosuppressive nature of the glioma microenvironment.
• Optimizing PD-1/PD-L1 inhibitor strategies may enhance treatment outcomes for glioma patients.